BUKWANG PHARMACEUTICAL IND CO.,LTD
Financials
Valuation Metrics
BUKWANG PHARMACEUTICAL IND CO.,LTD's Market Cap is ₩3932B. At end of 2025 it was ₩3734B. Ranked #544 of 2,421 in KR market (top 22%), #331 of 781 on KOSPI (top 42%), #57 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 25%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 393.18B KRW | KR#544/2,421 Sec#57/231 |
| Revenue | 215.09B KRW | KR#989/2,421 Sec#55/231 |
| Net Income | 8.70B KRW | KR#1,018/2,421 Sec#63/231 |
| Total Assets | 467.05B KRW | KR#801/2,421 Sec#48/231 |
| Net Assets | 334.39B KRW | KR#677/2,421 Sec#44/231 |
| Employees | 582 | KR#427/2,421 Sec#37/231 |
| Value | ||
| P/E | 45.19x | KR#1,398/2,421 Sec#90/231 |
| P/B | 1.18x | KR#1,597/2,421 Sec#106/231 |
| P/S | 1.83x | KR#1,755/2,421 Sec#101/231 |
| EV/EBITDA | 31.66x | KR#1,219/2,421 Sec#76/231 |
| FCF Yield | 3.61% | KR#944/2,421 Sec#57/231 |
| Profitability | ||
| ROE | 2.60% | KR#1,352/2,421 Sec#93/231 |
| ROA | 1.86% | KR#1,245/2,421 Sec#89/231 |
| Op. Margin | 5.42% | KR#914/2,421 Sec#69/231 |
| Revenue Growth | 20.05% | KR#553/2,421 Sec#52/231 |
| Earnings Growth | -31.88% | KR#990/2,421 Sec#64/231 |
| Financial Health | ||
| Debt Ratio | 39.67% | KR#782/2,421 Sec#91/231 |
| Total Debt | 79.82B KRW | KR#806/2,421 Sec#50/231 |
| FCF | 14.21B KRW | KR#619/2,421 Sec#33/231 |
| Cash | 104.10B KRW | KR#461/2,421 Sec#22/231 |
| Current Ratio | 2.33x | KR#746/2,421 Sec#88/231 |
| Net Debt/EBITDA | -2.08x | KR#229/2,421 Sec#9/231 |
| Dividend | ||
| Div. Yield | 3.12% | KR#614/2,421 Sec#28/231 |
| Performance | ||
| 1Y Return | 7.99% | KR#596/2,421 Sec#38/231 |
| 1M Return | -5.12% | KR#1,801/2,421 Sec#144/231 |
| From 52W High | -59.71% | KR#1,849/2,421 Sec#142/231 |
| 1Y MDD | -61.82% | KR#1,581/2,421 Sec#128/231 |
| Trading | ||
| Volume | 217,040 shares | KR#461/2,421 Sec#27/231 |
| Trading Value | 867.5M KRW | KR#759/2,421 Sec#76/231 |
| Foreign Own. | 6.77% | KR#658/2,421 Sec#57/231 |
| Per Share | ||
| EPS | 88 KRW | KR#1,444/2,421 Sec#97/231 |
| BPS | 3,389 KRW | KR#1,775/2,421 Sec#133/231 |
Company Info
Bugwang Pharm, established in 1960 for the purpose of manufacturing and selling pharmaceuticals, was listed on the Securities Market in 1988. The company holds four unlisted subsidiaries, including Denmark-based Contera Pharma A/S, Bugwang Medica Co., Ltd., JaguAHR Therapeutics, and ProteKt Therapeutics. It engages in the manufacturing and sales of pharmaceuticals and quasi-drugs, with major products including Dexid, Ferroba, Legalon, Latuda, and Tasenol. Bugwang Pharm is headquartered in Dongjak-gu, Seoul.